pharmareachllc.com

What It Is

Pharma Reach LLC is a pharmaceutical regulatory services provider headquartered in Fremont, California, positioning itself as a Silicon Valley company. According to the website copy, its team has experience in the pharmaceutical industry and mainly supports FDA regulatory compliance, product-related issues, inspection scheduling communications, and liaison work between companies and the FDA. It is worth noting that the crawled content does not present Pharma Reach LLC as a standard SaaS or enterprise software platform; it is closer to a professional consulting and registration agent service.

Core Features and Service Scope

Its core services include US Agent Services, Drug Firm Registration, Liaison with FDA, eCTD compilation and DMF submission, ANDA submissions, Regulatory Deficiencies Addressal, and Inspectional Observation Responses Addressal. The more valuable aspect is that it covers the common compliance chain for pharmaceutical companies entering the U.S. market: U.S. agent services, company registration, FDA communication, preparation and publishing of electronic submission documents, DMF/ANDA submissions, and responses to deficiencies and inspection observations.

Pricing, Trials, and Software Capabilities

The website does not disclose any plans, pricing, free tier, or trial information, nor does it explain whether fees are charged by project, by hour, or by submission type. Key SaaS dimensions such as third-party integrations, team collaboration permissions, cloud deployment/self-hosting, APIs, and developer support are also absent. Therefore, from an enterprise software perspective, its productization and transparency are relatively weak; from a regulatory consulting perspective, it appears to be a professional service that requires offline communication and a custom quote.

Pros and Cons

The advantage is that its service scenarios are focused on FDA pharmaceutical regulatory affairs, and it provides a company address, phone number, fax number, and email address, giving it a basic level of lead credibility. Its end-to-end positioning may suit companies that lack local U.S. regulatory communication capabilities. The drawbacks are limited information disclosure: it does not show client cases, team credentials, successful submission experience, service workflows, SLA, or data security measures, making it difficult to judge delivery quality and cost based on the official website alone.

Who It Is For and Access from China

It is more suitable for pharmaceutical companies planning to enter the U.S. market and needing support with FDA U.S. agent services, drug firm registration, DMF/ANDA/eCTD submissions, and deficiency responses—especially companies without a local U.S. regulatory team. The text does not make it possible to determine access conditions from China, and payment methods are not disclosed. Chinese companies may want to compare FDA registration agents, regulatory consulting firms, and eCTD submission service providers both in China and overseas, with particular attention to verifying credentials, case studies, pricing, and communication responsiveness.